Dan Theodorescu: Innovative approach we have named the Molecular Twin Precision Oncology Platform that creates a virtual replica of the patient using “multi-omic” data
Dan Theodorescu, Director at Cedars-Sinai Cancer Center, made the following post on LinkedIn:
“I am delighted to share that the paper ‘The Molecular Twin Artificial-intelligence Platform Integrates Multi-omic Data to Predict Outcomes for Pancreatic Adenocarcinoma Patients’ has been published in Nature Cancer. The paper describes an innovative approach we have named the Molecular Twin Precision Oncology Platform (MT-POP) that creates a virtual replica of the patient using “multi-omic” data, that is data from a variety of sources including clinical, surgical pathology, computational pathology, and molecular analysis of both normal host samples as well as the tumor. Moreover, the artificial intelligence architecture of the Molecular Twin Platform can absorb and analyze many data streams. In this study, application of the Molecular Twin on PDAC provided a novel biomarker panel based on serum proteins that surpassed the prognostic ability of current markers such as CA19-9. We are already adding and assessing the value of computational imaging and microbiome analysis in predicting outcomes.
A unique characteristic of the Molecular Twin architecture is its ability to tailor both the composition and number of analytes used to create predictive models. Evaluation of parsimonious models, models with the lowest number of analytes, revealed that such models can have equivalent predictive ability to the models that use the full dataset. Furthermore, we also showed that effective prediction could be carried out with only selected analyte combinations, and while reduced in performance, may be a first step in the march to democratizing precision oncology worldwide by reducing costs and complexity.
I would like to thank the team for making the tremendous effort to bring this concept to life and it is wonderful to see this research continue to develop with them. This work is an excellent example of the practical application of convergent science and the unique integration of different scientific disciplines. I am excited to push forward this cutting-edge field through the Convergent Science Cancer Consortium (CSCC) and the Convergent Science Virtual Cancer Center (CSVCC). Ultimately, it is my hope that the Molecular Twin can be tested on as many tumor types and treatments as possible and its performance evaluated. If successful, it holds the promise to improve precision oncology and make it available more broadly than ever before.”
Cedars-Sinai Cancer Center has published news posts that you can read.
Source: Dan Theodorescu/LinkedIn